1 Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. 2 UMR CNRS 5164, Université de Bordeaux, Bordeaux, France. 3 Agence de la Biomédecine, Saint-Denis La Plaine, France. 4 One Lambda, Inc., Canoga Park, CA. 5 Laboratoire d'histocompatibilité, Etablissement Français du Sang, Lyon, France. 6 Service de Néphrologie, Transplantation, Dialyse, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. 7 Address correspondence to: Jean-Luc Taupin, Pharm.D., Ph.D., Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France.
Transplantation. 2014 Oct 15;98(7):738-44. doi: 10.1097/TP.0000000000000229.
Single antigen flow beads assays may overestimate sensitization because of the detection of supposedly irrelevant antibodies recognizing denatured class I human leukocyte antigens (HLAs).
Sera of 323 HLA-sensitized kidney transplant candidates positive with a class I HLA single antigen flow beads assay were retested after acid treatment of the beads. Denatured HLA antibodies were identified according to ratio between the measured fluorescence intensity for treated and nontreated beads. T-lymphocyte flow cytometry crossmatches were performed to characterize the ability of these antibodies to recognize HLA on normal cells as a surrogate of their potential clinical relevance. Their impact on organ allocation was evaluated through a calculated panel reactive antibody. The utility of single antigen flow beads largely devoid of denatured HLA (iBeads) was also evaluated.
Denatured HLA antibodies were detected in 39% of the patients. They provided much less positive flow cytometry crossmatches than anti-native HLA antibodies (16% vs. 83%, P<0.0001). Removing the HLA-A and HLA-B antigens targeted by denatured HLA antibodies from unacceptable antigens lowered the calculated panel reactive antibody for 90 patients, sometimes dramatically. The iBeads assay demonstrated nearly the same ability to predict crossmatch results than the acid treatment assay.
Denatured class I HLA antibodies are common, but the antigens they target should not be considered as unacceptable in most cases, because they negatively impact access to a transplant while predominantly providing negative sensitive crossmatches. The iBeads assay seems to be a valuable alternative to better define unacceptable antigens.
由于单抗原流珠检测可能会检测到识别变性 I 类人白细胞抗原(HLA)的所谓无关抗体,因此可能会高估致敏。
对 323 名 HLA 致敏的肾移植候选者的血清进行了一项 I 类 HLA 单抗原流珠检测,如果呈阳性,则在对珠子进行酸处理后进行重新检测。根据处理和未处理珠子的测量荧光强度之间的比值来鉴定变性 HLA 抗体。进行 T 淋巴细胞流式细胞术交叉匹配以表征这些抗体识别正常细胞上 HLA 的能力,作为其潜在临床相关性的替代物。通过计算面板反应性抗体评估它们对器官分配的影响。还评估了大大缺乏变性 HLA 的单抗原流珠(iBeads)的用途。
在 39%的患者中检测到变性 HLA 抗体。它们提供的流式细胞术交叉匹配阳性率远低于抗天然 HLA 抗体(16%比 83%,P<0.0001)。从不可接受的抗原中去除变性 HLA 抗体针对的 HLA-A 和 HLA-B 抗原,降低了 90 名患者的计算面板反应性抗体,有时会显著降低。iBeads 检测与酸处理检测具有几乎相同的预测交叉匹配结果的能力。
变性 I 类 HLA 抗体很常见,但在大多数情况下,不应将其针对的抗原视为不可接受,因为它们会降低移植的机会,而主要提供阴性敏感的交叉匹配。iBeads 检测似乎是一种更好地定义不可接受抗原的有价值的替代方法。